VIANAUTIS
ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers such as the blood-brain barrier (BBB). PolyNaut, a versatile nano-engineered polymer technology that facilitates intracellular delivery, is used in collaboration with a number of partners. SomaServe is breaking new ground in the development of medications that can bypass various biological barriers and provide significant therapeutic benefits thanks to this technology.
VIANAUTIS
Social Links:
Industry:
Biopharma Biotechnology Medical
Founded:
2018-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.vianautis.com
Total Employee:
11+
Status:
Active
Total Funding:
22.1 M GBP
Technology used in webpage:
Person Schema Pound Sterling Kmedia Tech
Similar Organizations
Enterin
Philadelphia-based biotechnology company .
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Employees Featured
Investors List
Eli Lilly
Eli Lilly investment in Series A - ViaNautis
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Series A - ViaNautis
Origin Capital
Origin Capital investment in Series A - ViaNautis
Meltwind Advisory
Meltwind Advisory investment in Series A - ViaNautis
UCB Ventures
UCB Ventures investment in Series A - ViaNautis
BGF Ventures
BGF Ventures investment in Series A - ViaNautis
4BIO Capital
4BIO Capital investment in Series A - ViaNautis
O2h Ventures
O2h Ventures investment in Series A - ViaNautis
Abcam
Abcam investment in Series A - ViaNautis
O2h Ventures
O2h Ventures investment in Series A - ViaNautis
Official Site Inspections
http://www.vianautis.com
- Host name: wpx.net
- IP address: 194.1.147.24
- Location: Chicago United States
- Latitude: 41.8719
- Longitude: -87.6589
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60607
More informations about "ViaNautis"
About Us < ViaNautis
ViaNautis was established in 2018 as SomaServe, a spin-off from UCL by founders Dr Francesca Crawford, Professor Giuseppe Battaglia and Dr Denis Cecchin. …to a thriving biotech. …See details»
Vianautis - LinkedIn
Vianautis | 1,577 followers on LinkedIn. Targeted Nanomedicines | ViaNautis, formerly known as SomaServe, was founded in 2018 as a spin-off from UCL under the leadership of CEO and …See details»
ViaNautis - Crunchbase Company Profile & Funding
ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers such as the blood-brain barrier (BBB). PolyNaut, a versatile nano-engineered polymer …See details»
Contact Us - ViaNautis
[email protected]. LinkedIn. Cadence, Unity Campus Cambridge, CB22 3FT, UK. ViaNautis Bio Ltd. Cadence, Unity Campus Cambridge CB22 3FT, UK. [email protected]. LinkedIn. News …See details»
ViaNautis - VentureRadar
ViaNautis Bio is a nanomedicine company that has developed the proprietary polyNaut drug delivery platform. This platform utilizes advanced polymer materials and in silico screening to …See details»
Groundbreaking nanomedicine company ViaNautis lands at Unity …
Jul 15, 2024 What have been ViaNautis' biggest milestones to date? Scientifically, our most significant milestone to date has been establishing the feasibility to use our technology for …See details»
Series A - ViaNautis - 2023-11-13 - Crunchbase Funding Round …
Nov 13, 2023 Organization Name . ViaNautis . Announced Date Nov 13, 2023; Closed On Date Nov 14, 2023; Funding Type Series A; Funding Stage Early Stage Venture; Money Raised . …See details»
CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore …
Nov 13, 2023 The Cystic Fibrosis Foundation is investing up to $3 million in ViaNautis for preclinical research into its non-viral, genetic therapy delivery mechanism called polyNaut ®. …See details»
ViaNautis Bio announces $25 million Series A financing to drive …
Cambridge UK, 13 November 2023 – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, is excited to …See details»
ViaNautis eyes fresh hires as it continues to grow
May 19, 2025 Encouragingly, ViaNautis anticipates achieving key value-inflection points in 2025 and 2026 as it progresses plans to advance into the clinic. In this respect, the company plans …See details»
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly
Oct 28, 2024 Dr Francesca Crawford, co-founder of ViaNautis, added, "This collaboration with Lilly is a testament to our polyNaut® platform, which is also driving a highly differentiated …See details»
4BIO Capital jointly leads $25 million Series A financing of …
London & Cambridge, UK, 13 November 2023 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in …See details»
ViaNautis | VentureRadar
ViaNautis Bio is a nanomedicine company that has developed the proprietary polyNaut drug delivery platform. This platform utilizes advanced polymer materials and in silico screening to …See details»
ViaNautis Bio Signs Strategic Collaboration Agreement with
Oct 28, 2024 Dr Francesca Crawford, co-founder of ViaNautis, commented: "This collaboration with Lilly is a testament to our polyNaut® platform, which is also driving a highly differentiated …See details»
News & Events - ViaNautis
Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types. ViaNautis Appoints Ray Jupp as Chief …See details»
Nanomedicine Company ViaNautis Raises Series A Financing - BGF
Nov 13, 2023 ViaNautis Bio, a ground-breaking nanomedicine company at the forefront of genetic therapies, has completed its Series A funding round, raising £20 million. Formerly …See details»
ViaNautis signs multi-year collaboration with Eli Lilly and Company
Oct 31, 2024 ViaNautis CEO, Dr Adi Hoess, added: “I am very excited about our collaboration with Lilly to develop novel genetic medicines for patients in need. I want to thank Fran and the …See details»
News Archives - ViaNautis
Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types. ViaNautis Appoints Ray Jupp as Chief …See details»
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to ...
Oct 28, 2024 Under the terms of the agreement, ViaNautis will receive an initial upfront payment from Lilly, with the short-term potential for additional payments including research-based …See details»